March 2017 Investigators have shown that 2-AG, an endocannabinoid (i.e., a cannabinoid manufactured within the body, as opposed to plant-derived), augments the cocaine-induced dopamine surge in the brain’s reward system.
The discovery adds to evidence that inhibiting activity in the endocannabinoid system might reduce cocaine’s rewarding and addictive effects.
January 2016 Giving mice a modified version of a naturally occurring gene blocks cocaine’s stimulant effects without affecting the animals’ physiological or metabolic health. The new evidence advances the proposed therapy a step closer to readiness for testing in people.
June 2014 Two recent studies suggest that genotyping may enable clinicians to base therapies on individual patients’ potential responsiveness to opioid drugs’ therapeutic effects and vulnerability to their harmful effects.
April 2010 Describes a literature analysis reporting on the prevalence of people with bipolar disorder who also have a substance use disorder and discusses the genetic link that may contribute to this comorbidity.
December 2008 Remembers Henry I. "Hank" Yamamura, an eminent neuropharmacologist who pioneered radioligand binding assays, contributing valuable knowledge about neurotransmitter transporters and receptors.
September 2008 Describes research findings demonstrating that the immune system participates in the shaping of brain circuits during a child's development, a finding that may shed light on the origins of neurodegenerative diseases.